{
  "ticker": "TYP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969674",
  "id": "02969674",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250716",
  "time": "0853",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250716/pdf/06lv2nk20crkqj.pdf",
  "summary": "### Summary of ASX Announcement:  \n\n**Announcement Type:** Leadership/Team Appointment  \n\n**Material Information:**  \n- Two key appointments to strengthen **TRP-8803 clinical development**:  \n  - **Professor Marcel Mozafari** as **Senior Formulation Scientist** (full-time).  \n  - **Professor David Castle** as **Consultant Medical Officer** (part-time, existing SAB member).  \n2. Appointments timed to support **world-first clinical trial** for **TRP-8803** (IV-infused psilocin) in treating **Binge Eating Disorder** (collaboration with Swinburne University).  \n\n**Impact:** Operational strengthening for clinical progress; no direct capital/financial implications.  \n\n**Omitted:** Background details, management commentary, risk disclosures (non-material to trading decisions).  \n\n**Verdict:** Neutral update\u2014reinforces execution capability but no immediate capital markets impact.",
  "usage": {
    "prompt_tokens": 2374,
    "completion_tokens": 193,
    "total_tokens": 2567,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-15T23:15:59.218256"
}